BioSpace News Archive

BeiGene, Ltd. today announced that it will host an investor conference call and webcast on Thursday, July 9, 2020 at 9:00 a.m. ET to discuss the Company’s early development pipeline and research.

Study design presented at the ESMO World Congress on Gastrointestinal Cancer2020

Exclusive worldwide license enables Sarepta to develop and promote imlifidase as a pre-treatment for gene therapy in Duchenne and Limb-girdle muscular dystrophy patients who have pre-existing antibodies to AAV

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced an update on its clinical development plan for Annamycin.

Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage rare and unmet needs-focused gastroenterology company, today announced that the Executive Management team will participate in the Hidden Gems in Healthcare Conference Call Series hosted by Gary Nachman and BMO Capital Markets on Thursday, July 9, 2020. Please see additional details below: Hidden Gems in Healthcare Conference Call Series Dat

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Executive Directors of the company will present at several r

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Bl

PRINCE study enrolled 53 patients . Trial designed to further establish the potential of pegcetacoplan, a targeted C3 therapy, in all patients living with PNH Top-line results expected in early 2021 WALTHAM, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the completion of enrollment in the global Phase 3 PRINCE study, which is evaluating pegcetacoplan (APL-2)

Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the company’s SARS-CoV-2 RT-PCR test. Prof. Arndt Rolfs, CEO of CENTOGENE, sai

Tongji Healthcare Group, Inc. (OTC: TONJ) (the “Company”) is pleased to announce the appointment of new board members and officers, effective as of June 18, 2020.